Compare SPH & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPH | EYPT |
|---|---|---|
| Founded | 1945 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 1996 | 2005 |
| Metric | SPH | EYPT |
|---|---|---|
| Price | $20.42 | $15.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $31.00 |
| AVG Volume (30 Days) | 143.2K | ★ 1.7M |
| Earning Date | 05-07-2026 | 05-18-2026 |
| Dividend Yield | ★ 6.42% | N/A |
| EPS Growth | ★ 42.11 | N/A |
| EPS | ★ 0.69 | N/A |
| Revenue | ★ $1,432,518,000.00 | $7,539,000.00 |
| Revenue This Year | $2.06 | N/A |
| Revenue Next Year | $1.64 | $965.51 |
| P/E Ratio | $29.45 | ★ N/A |
| Revenue Growth | ★ 7.94 | N/A |
| 52 Week Low | $17.30 | $3.91 |
| 52 Week High | $21.72 | $19.11 |
| Indicator | SPH | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 54.94 | 46.88 |
| Support Level | $17.86 | $14.06 |
| Resistance Level | $20.59 | $18.99 |
| Average True Range (ATR) | 0.42 | 1.23 |
| MACD | -0.03 | -0.10 |
| Stochastic Oscillator | 60.21 | 28.75 |
Suburban Propane Partners LP distributes propane, renewable propane, renewable natural gas (RNG), fuel oil, refined fuels, and markets natural gas and electricity in deregulated markets. It produces and invests in low-carbon fuel alternatives. The company installs and services home comfort heating and ventilation equipment and distributes fuel oil, kerosene, diesel, and gasoline to about 25,000 residential and commercial customers mainly in the U.S. northeast. It operates three segments: Propane, Fuel Oil and Refined Fuels, and Natural Gas and Electricity, with the Propane segment generating the majority of revenue. Propane, a by-product of natural gas processing and petroleum refining, is a clean-burning energy source known for transportability and ease of use.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.